| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0005000 | Intron-Exon-Intron | chr6:4891113-4892613 | chr6:4890879-4892379 | 58 nt | 0.3966 |
| hsa_CDYL_0005100 | Intron-Exon-Intron | chr6:4891500-4892613 | chr6:4891266-4892379 | 1114 nt | 0.4964 |
| hsa_CDYL_0005800 | Exon-Exon | chr6:4891947-4892337 | chr6:4891713-4892103 | 391 nt | 0.4859 |
| hsa_CDYL_0006000 | Intron-Exon-Intron | chr6:4891947-4894274 | chr6:4891713-4894040 | 559 nt | 0.4794 |
| hsa_CDYL_0006100 | Intron-Exon-Intron | chr6:4891947-4896696 | chr6:4891713-4896462 | 478 nt | 0.4895 |
| hsa_CDYL_0005600 | Intron-Exon-Intron | chr6:4891947-4896721 | chr6:4891713-4896487 | 250 nt | 0.3920 |
| hsa_CDYL_0006200 | Intron-Exon-Intron | chr6:4891947-4897442 | chr6:4891713-4897208 | 252 nt | 0.4325 |
| hsa_CDYL_0006300 | Intron-Exon-Intron | chr6:4891947-4906617 | chr6:4891713-4906383 | 107 nt | 0.3925 |
| hsa_CDYL_0005700 | Intron-Exon-Intron | chr6:4891947-4909043 | chr6:4891713-4908809 | 250 nt | 0.3920 |
| hsa_CDYL_0006400 | Intron-Exon-Intron | chr6:4891947-4909184 | chr6:4891713-4908950 | 915 nt | 0.5377 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].